Testing disagreements hamper Ebola vax search; Admedus begins PhII trial of herpes jab;

> As the Ebola outbreak wanes, disagreements over the most effective testing methods may mean potential vaccines aren't thoroughly vetted. Story

> Admedus Limited will begin a Phase II study of its herpes vaccine this month. More

> Research Triangle Park, NC-based Argos Therapeutics ($ARGS) struck a deal with China-based Lummy Hong Kong to develop cancer immunotherapies in China. Report

> Daiichi Sankyo and Terumo announced their application for manufacturing and sales approval of an intradermal seasonal influenza vaccine in Japan. Release

> GeoVax will seek a dual pathway for advancing its HIV vaccine into human trials. Release

> Scientists believe a new HIV treatment pioneered using an antibody to attack the virus could lead to a vaccine to prevent the infection. Story

And Finally... Los Angeles artist Mary Beth Heffernan delivered a way for Ebola patients to see the faces of those helping. Story

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.